Attached files
| file | filename |
|---|---|
| EX-10.11 - EX-10.11 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex1011.htm |
| EX-32.1 - EX-32.1 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex321.htm |
| EX-31.2 - EX-31.2 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex312.htm |
| EX-31.1 - EX-31.1 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex311.htm |
| EX-23.1 - EX-23.1 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex231.htm |
| EX-21.0 - EX-21.0 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex21.htm |
| EX-10.12 - EX-10.12 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex1012.htm |
| EX-10.10 - EX-10.10 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex1010.htm |
| EX-10.9 - EX-10.9 - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231xex109.htm |
| 10-K - 10-K - SUPERNUS PHARMACEUTICALS, INC. | supn-20201231.htm |
EXHIBIT 32.2
SUPERNUS PHARMACEUTICALS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. sec. 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Supernus Pharmaceuticals, Inc. (the "Company") on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James P. Kelly, Executive Vice-President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: March 8, 2021 | By: | /s/ JAMES P. KELLY | ||||||
James P. Kelly Executive Vice-President and Chief Financial Officer | ||||||||